Orient Pharma Co Stock Probability Of Bankruptcy
| 4166 Stock | TWD 37.00 0.05 0.14% |
Orient |
Orient Pharma Co Company odds of financial turmoil Analysis
Orient Pharma's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current Orient Pharma Probability Of Bankruptcy | Less than 27% |
Most of Orient Pharma's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Orient Pharma Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Orient Pharma probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Orient Pharma odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Orient Pharma Co financial health.
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
| Competition |
Based on the latest financial disclosure, Orient Pharma Co has a Probability Of Bankruptcy of 27.0%. This is 37.63% lower than that of the Healthcare sector and 34.35% lower than that of the Drug Manufacturers - Major industry. The probability of bankruptcy for all Taiwan stocks is 32.21% higher than that of the company.
Orient Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Orient Pharma's direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Orient Pharma could also be used in its relative valuation, which is a method of valuing Orient Pharma by comparing valuation metrics of similar companies.Orient Pharma is currently under evaluation in probability of bankruptcy category among its peers.
Orient Fundamentals
| Return On Equity | -14.97 | |||
| Return On Asset | -8.89 | |||
| Profit Margin | (61.79) % | |||
| Operating Margin | (79.63) % | |||
| Current Valuation | 3.23 B | |||
| Shares Outstanding | 156.01 M | |||
| Price To Book | 2.74 X | |||
| Price To Sales | 10.53 X | |||
| Revenue | 285.29 M | |||
| Gross Profit | 5.66 M | |||
| EBITDA | (166.81 M) | |||
| Net Income | (176.29 M) | |||
| Cash And Equivalents | 64.58 M | |||
| Cash Per Share | 0.41 X | |||
| Total Debt | 287.34 M | |||
| Debt To Equity | 26.20 % | |||
| Current Ratio | 1.18 X | |||
| Book Value Per Share | 7.03 X | |||
| Cash Flow From Operations | (192.55 M) | |||
| Earnings Per Share | (1.13) X | |||
| Number Of Employees | 13 | |||
| Beta | 0.62 | |||
| Market Capitalization | 3 B | |||
| Z Score | 6.0 |
About Orient Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Orient Pharma Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Orient Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Orient Pharma Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Orient Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Orient Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Orient Pharma will appreciate offsetting losses from the drop in the long position's value.Moving against Orient Stock
| 0.89 | 4102 | Yung Zip Chemical | PairCorr |
| 0.85 | 2884 | ESUN Financial Holding | PairCorr |
| 0.77 | 4108 | Phytohealth Corp | PairCorr |
The ability to find closely correlated positions to Orient Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Orient Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Orient Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Orient Pharma Co to buy it.
The correlation of Orient Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Orient Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Orient Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Orient Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Orient Stock Analysis
When running Orient Pharma's price analysis, check to measure Orient Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Orient Pharma is operating at the current time. Most of Orient Pharma's value examination focuses on studying past and present price action to predict the probability of Orient Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Orient Pharma's price. Additionally, you may evaluate how the addition of Orient Pharma to your portfolios can decrease your overall portfolio volatility.